ArticleBJC reports2024

Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.

Dana M Roque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.